Treatment of acquired hemophilia A, a balancing act

Autor: Schep, S.J., Dijk, W.E.M. van, Beckers, E.A.M., Meijer, K., Coppens, M., Eikenboom, J., Leebeek, F.W.G., Vulpen, L.F.D. van, Fischer, K.F., Schutgens, R.E.G., Dutch Soc Haemophilia Treaters

Publikováno v: American Journal of Hematology, 96(1), 51-59. WILEY
American Journal of Hematology
American Journal of Hematology, 96(1), 51-59. Wiley
American Journal of Hematology, 96(1), 51-59. Wiley-Liss Inc.
American journal of hematology, 96(1), 51-59. Wiley-Liss Inc.

Acquired hemophilia A (AHA) is a severe auto‐immune bleeding disorder. Treatment of AHA is burdensome and optimal management is still unresolved. Therefore a retrospective nationwide multi‐center cohort study (1992‐2018) was performed to evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe0d051262d6bd495f7a8137ac4a7fe
https://research.rug.nl/en/publications/6cf7b942-aa55-4895-8026-19d485ddac6c